She Tried all Cancer Treatment for Chordoma Bone Cancer and Finally Won Her Battle with ECCT.
A 35-year-old woman who faced the challenges of a malignant chordoma diagnosis. Her journey began in February 2015 when she presented symptoms of shortness of breath and severe back pain. A CT scan revealed a mass in the T1-T3 vertebral corpuscles, causing destruction and exerting pressure on the esophagus and trachea. Subsequent biopsy results confirmed the presence of chordoma.
In March 2015, she underwent a single level anterior cervical discectomy and graft cage replacement. Following the surgery, a course of 25 days of radiotherapy (RT) was administered. Unfortunately, the post-RT MRI indicated that the condition had progressed. Determined to combat the disease, she embarked on a 3-year chemotherapy regimen, including 2 years of sunitinib, followed by 6 months of sorafenib, and another 6 months of imatinib. However, the tumor remained resilient.
In March 2021, a lesion resulting from a pathological fracture in her left femur confirmed the persistence of chordoma. By September 2021, her condition had worsened significantly, with a 6.5 cm mass lesion destroying the S1 vertebral body and left lateral elements. Additionally, a nodular lytic lesion of 1.5 cm appeared in the posterior of the left transverse process of the L5 vertebra. The existing lesions had also grown larger, measuring 7.5x5 cm.
In January 2022, a relapse was detected as a 13x9 mm mass in the middle part of her left femur. She began a regimen of cyclophosphamide and etoposide, but despite her efforts, the cancer continued its progression, affecting her femur and sacrum. Frustratingly, the mass sizes continued to increase despite her treatments.
A turning point arrived in February 2022 when Natalie decided to try ECCT. Remarkably, her mediastinal, sacral, and femoral lesions started to regress in size. Previously wheelchair-bound, she regained her ability to walk unassisted thanks to ECCT.
Notably, her pain levels decreased significantly, resulting in reduced dependence on pain medication.
Before ECCT, her condition was marked by persistent progression and treatment resistance. With the introduction of ECCT, both clinical and radiological responses became evident. The tumors began to shrink, and Natalie experienced a remarkable improvement in her quality of life, regaining mobility and independence that had once seemed lost.